{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:32:03Z","timestamp":1792873923324,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The strategic Priority Research Program of the chinese academy of sciences","award":["XDB0490000"],"award-info":[{"award-number":["XDB0490000"]}]},{"name":"the National Key R&D Program of China","award":["2022YFC3500804"],"award-info":[{"award-number":["2022YFC3500804"]}]},{"name":"USTC Research Funds of the Double First-Class Initiative","award":["YD9100002040"],"award-info":[{"award-number":["YD9100002040"]}]},{"name":"Hubei Provincial health Research Fund","award":["WJ2025Z018"],"award-info":[{"award-number":["WJ2025Z018"]}]},{"name":"The Joint Laboratory of innovation in Life Sciences of USTC and Changchun Zhuoyi Biological Co.Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in infants and elderly individuals. Although nirsevimab represents a recent breakthrough against RSV infection, the emergence of resistant variants highlight the need for additional antiviral strategies. Here, we report two nanobodies (Nbs), 1G9 and 1D8, that target the RSV fusion (F) protein and exhibit high neutralizing activity against RSV subtypes. In vivo, the Nbs-Fc demonstrated robust prophylactic and therapeutic efficacy. Cryo-electron microscopy revealed that 1G9 and 1D8 specifically engage a conformational pivot site within antigenic site IV, crosslinking the metastable heptad repeats B (HRB) and the conformationally stable domain II of the F protein. This interaction stabilizes the prefusion conformation and prevents the structural rearrangement required for membrane fusion. Notably, the binding residues are highly conserved across RSV subtypes, accounting for the broad-spectrum neutralization observed. Together, our findings identify a structurally conserved and functionally critical epitope on RSV F and highlight 1G9 and 1D8 as promising candidates for next-generation prophylactic and therapeutic interventions against RSV.<\/jats:p>","DOI":"10.1038\/s44321-026-00412-w","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:01:10Z","timestamp":1775566870000},"page":"1866-1883","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Broadly neutralizing nanobodies target a defined structural pivot site on the RSV fusion protein"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4060-7548","authenticated-orcid":false,"given":"Qianqian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Entao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengchuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-2971","authenticated-orcid":false,"given":"Bo","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9034-5755","authenticated-orcid":false,"given":"Sandra","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"412_CR1","doi-asserted-by":"crossref","unstructured":"IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531\u2013537","DOI":"10.1542\/peds.102.3.531"},{"key":"412_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, Adams PD (2018) Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol 74:531\u2013544","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"412_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1542\/peds.2014-1665","volume":"134","author":"American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C","year":"2014","unstructured":"American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415\u2013420","journal-title":"Pediatrics"},{"issue":"Pt 5","key":"412_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1099\/0022-1317-73-5-1177","volume":"73","author":"K Anderson","year":"1992","unstructured":"Anderson K, Stott EJ, Wertz GW (1992) Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage. J Gen Virol 73(Pt 5):1177\u20131188","journal-title":"J Gen Virol"},{"key":"412_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","volume":"17","author":"MB Battles","year":"2019","unstructured":"Battles MB, McLellan JS (2019) Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol 17:233\u2013245","journal-title":"Nat Rev Microbiol"},{"key":"412_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40387-y","volume":"9","author":"L Bin","year":"2019","unstructured":"Bin L, Liu H, Tabor DE, Tovchigrechko A, Qi Y, Ruzin A, Esser MT, Jin H (2019) Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015-17. Sci Rep 9:3898","journal-title":"Sci Rep"},{"key":"412_CR7","first-page":"3","volume":"372","author":"PL Collins","year":"2013","unstructured":"Collins PL, Fearns R, Graham BS (2013) Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372:3\u201338","journal-title":"Curr Top Microbiol Immunol"},{"key":"412_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature12442","volume":"501","author":"D Corti","year":"2013","unstructured":"Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, Guarino B, Silacci C, Marcandalli J, Marsland BJ et al (2013) Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501:439\u2013443","journal-title":"Nature"},{"key":"412_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.hlife.2023.09.003","volume":"1","author":"L Dai","year":"2023","unstructured":"Dai L, Song J, Xu L et al (2023) A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein. hLife 1:12\u201325","journal-title":"hLife"},{"key":"412_CR10","doi-asserted-by":"publisher","first-page":"23514","DOI":"10.1074\/jbc.M604292200","volume":"281","author":"WF Dall\u2019Acqua","year":"2006","unstructured":"Dall\u2019Acqua WF, Kiener PA, Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514\u201323524","journal-title":"J Biol Chem"},{"key":"412_CR11","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","volume":"169","author":"WF Dall\u2019Acqua","year":"2002","unstructured":"Dall\u2019Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171\u20135180","journal-title":"J Immunol"},{"key":"412_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","volume":"60","author":"L Detalle","year":"2016","unstructured":"Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K et al (2016) Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother 60:6\u201313","journal-title":"Antimicrob Agents Chemother"},{"key":"412_CR13","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486\u2013501","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"412_CR14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/infdis\/jiac488","volume":"227","author":"J Fullarton","year":"2023","unstructured":"Fullarton J, Keary I, Paes B, Tarride JE, Carbonell-Estrany X, Rodgers-Gray B (2023) Accurately assessing the expected impact of universal first respiratory syncytial virus (RSV) season immunization with nirsevimab against RSV-related outcomes and costs among all US infants. J Infect Dis 227:1333\u20131334","journal-title":"J Infect Dis"},{"key":"412_CR15","doi-asserted-by":"publisher","first-page":"e1005035","DOI":"10.1371\/journal.ppat.1005035","volume":"11","author":"MS Gilman","year":"2015","unstructured":"Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, Zhu Q, Kabeche SC, Kumar A, Palomo C et al (2015) Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11:e1005035","journal-title":"PLoS Pathog"},{"key":"412_CR16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/374168a0","volume":"374","author":"AS Greenberg","year":"1995","unstructured":"Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF (1995) A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374:168\u2013173","journal-title":"Nature"},{"key":"412_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simoes EAF, Esser MT, Khan AA, Dubovsky F et al (2020) Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 383:415\u2013425","journal-title":"N Engl J Med"},{"key":"412_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1955812","volume":"13","author":"W Harshbarger","year":"2021","unstructured":"Harshbarger W, Abeyrathne PD, Tian S, Huang Y, Chandramouli S, Bottomley MJ, Malito E (2021) Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein. MAbs 13:955812","journal-title":"MAbs"},{"key":"412_CR19","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.3389\/fimmu.2019.02778","volume":"10","author":"J Huang","year":"2019","unstructured":"Huang J, Diaz D, Mousa JJ (2019) Antibody epitopes of pneumovirus fusion proteins. Front Immunol 10:2778","journal-title":"Front Immunol"},{"key":"412_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s12519-023-00743-5","volume":"19","author":"MY Jiang","year":"2023","unstructured":"Jiang MY, Duan YP, Tong XL, Huang QR, Jia MM, Yang WZ, Feng LZ (2023) Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis. World J Pediatr 19:1030\u20131040","journal-title":"World J Pediatr"},{"key":"412_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1086\/514115","volume":"176","author":"S Johnson","year":"1997","unstructured":"Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O\u2019Grady J, Koenig S, Tamura JK et al (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215\u20131224","journal-title":"J Infect Dis"},{"key":"412_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nsmb.3267","volume":"23","author":"MG Joyce","year":"2016","unstructured":"Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet EJ, Tsybovsky Y et al (2016) Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol 23:811\u2013820","journal-title":"Nat Struct Mol Biol"},{"key":"412_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995412","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Humphries F, Girardin RC, Wallace A, Ejemel M, Amcheslavsky A, McMahon CT, Schiller ZA, Ma Z, Cruz J et al (2022a) Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants. Front Immunol 13:995412","journal-title":"Front Immunol"},{"key":"412_CR24","doi-asserted-by":"publisher","first-page":"e1031","DOI":"10.1016\/S2214-109X(19)30264-5","volume":"7","author":"Y Li","year":"2019","unstructured":"Li Y, Reeves RM, Wang X, Bassat Q, Brooks WA, Cohen C, Moore DP, Nunes M, Rath B, Campbell H et al (2019) Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health 7:e1031\u2013e1045","journal-title":"Lancet Glob Health"},{"key":"412_CR25","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simoes EAF, Campbell H et al (2022b) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399:2047\u20132064","journal-title":"Lancet"},{"key":"412_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155190","volume":"123","author":"Y Lu","year":"2024","unstructured":"Lu Y, Wu Y, Huang M, Chen J, Zhang Z, Li J, Yang R, Liu Y, Cai S (2024) Fuzhengjiedu formula exerts protective effect against LPS-induced acute lung injury via gut-lung axis. Phytomedicine 123:155190","journal-title":"Phytomedicine"},{"key":"412_CR27","doi-asserted-by":"crossref","unstructured":"Ma H, Zeng W, Meng X, Huang X, Yang Y, Zhao D, Zhou P, Wang X, Zhao C, Sun Y et al (2021) Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain. J Virol 95:10-1128","DOI":"10.1128\/JVI.02438-20"},{"key":"412_CR28","doi-asserted-by":"publisher","first-page":"12236","DOI":"10.1128\/JVI.01579-10","volume":"84","author":"JS McLellan","year":"2010","unstructured":"McLellan JS, Chen M, Chang JS, Yang Y, Kim A, Graham BS, Kwong PD (2010) Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol 84:12236\u201312244","journal-title":"J Virol"},{"key":"412_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A et al (2013a) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592\u2013598","journal-title":"Science"},{"key":"412_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T et al (2013b) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113\u20131117","journal-title":"Science"},{"key":"412_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/protein\/gzy017","volume":"31","author":"LS Mitchell","year":"2018","unstructured":"Mitchell LS, Colwell LJ (2018) Analysis of nanobody paratopes reveals greater diversity than classical antibodies. Protein Eng Des Sel 31:267\u2013275","journal-title":"Protein Eng Des Sel"},{"key":"412_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.271","volume":"2","author":"JJ Mousa","year":"2017","unstructured":"Mousa JJ, Kose N, Matta P, Gilchuk P, Crowe JE Jr (2017) A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol 2:16271","journal-title":"Nat Microbiol"},{"key":"412_CR33","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMc2214773","volume":"388","author":"WJ Muller","year":"2023","unstructured":"Muller WJ, Madhi SA, Seoane Nunez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL, Llapur CJ, Novoa JM, Saez Llorens X et al (2023) Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med 388:1533\u20131534","journal-title":"N Engl J Med"},{"key":"412_CR34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S (2013) Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82:775\u2013797","journal-title":"Annu Rev Biochem"},{"key":"412_CR35","first-page":"73","volume":"6","author":"O Ogunsemowo","year":"2018","unstructured":"Ogunsemowo O, Olaleye DO, Odaibo GN (2018) Human respiratory syncytial virus subtypes A and B infection among children attending primary and secondary health care facilities in Ibadan, Nigeria. Arch Basic Appl Med 6:73\u201378","journal-title":"Arch Basic Appl Med"},{"key":"412_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1146\/annurev-immunol-051116-052206","volume":"35","author":"PJM Openshaw","year":"2017","unstructured":"Openshaw PJM, Chiu C, Culley FJ, Johansson C (2017) Protective and harmful immunity to RSV infection. Annu Rev Immunol 35:501\u2013532","journal-title":"Annu Rev Immunol"},{"key":"412_CR37","doi-asserted-by":"publisher","first-page":"2140533","DOI":"10.1080\/21645515.2022.2140533","volume":"18","author":"ER Packnett","year":"2022","unstructured":"Packnett ER, Winer IH, Larkin H, Oladapo A, Gonzales T, Wojdyla M, Goldstein M, Smith VC (2022) RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020. Hum Vaccin Immunother 18:2140533","journal-title":"Hum Vaccin Immunother"},{"key":"412_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA (2017) cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14:290\u2013296","journal-title":"Nat Methods"},{"key":"412_CR39","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1099\/jgv.0.000959","volume":"98","author":"B Rima","year":"2017","unstructured":"Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, Lee B, Maisner A, Rota P, Wang L et al (2017) ICTV virus taxonomy profile: pneumoviridae. J Gen Virol 98:2912\u20132913","journal-title":"J Gen Virol"},{"key":"412_CR40","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1128\/AAC.01285-13","volume":"57","author":"GJ Robbie","year":"2013","unstructured":"Robbie GJ, Criste R, Dall\u2019acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP (2013) A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147\u20136153","journal-title":"Antimicrob Agents Chemother"},{"key":"412_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14158","volume":"8","author":"I Rossey","year":"2017","unstructured":"Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA et al (2017a) Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun 8:14158","journal-title":"Nat Commun"},{"key":"412_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16165","volume":"8","author":"I Rossey","year":"2017","unstructured":"Rossey I, Gilman MSA, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, Chen M, Mas V, Spitaels J, Melero JA et al (2017b) Corrigendum: Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun 8:16165","journal-title":"Nat Commun"},{"key":"412_CR43","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s42003-021-02399-1","volume":"4","author":"R Sanchez-Garcia","year":"2021","unstructured":"Sanchez-Garcia R, Gomez-Blanco J, Cuervo A, Carazo JM, Sorzano COS, Vargas J (2021) DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun Biol 4:874","journal-title":"Commun Biol"},{"key":"412_CR44","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T, McAllister DA, O\u2019Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C et al (2017) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 390:946\u2013958","journal-title":"Lancet"},{"key":"412_CR45","unstructured":"Sominina AA, Sukhubaevskaia LP, Samoilovich MP, Klimovich VB, Monaenkov AO, Amosova IV, Markina IA, Bubnova SD, Zibina EA, Ostrova IV (1995) Characteristics of monoclonal antibodies to RS virus in immunoenzyme and immunofluorescence techniques. Vestn Ross Akad Med Nauk 9:49\u201354"},{"key":"412_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00006454-199802000-00006","volume":"17","author":"KN Subramanian","year":"1998","unstructured":"Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr, Carlin D et al (1998) Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 17:110\u2013115","journal-title":"Pediatr Infect Dis J"},{"key":"412_CR47","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1099\/0022-1317-82-6-1375","volume":"82","author":"RJ Sugrue","year":"2001","unstructured":"Sugrue RJ, Brown C, Brown G, Aitken J, Mc LRHW (2001) Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells. J Gen Virol 82:1375\u20131386","journal-title":"J Gen Virol"},{"key":"412_CR48","doi-asserted-by":"crossref","unstructured":"Suleiman-Martos N, Caballero-Vazquez A, Gomez-Urquiza JL, Albendin-Garcia L, Romero-Bejar JL, Canadas-De la Fuente GA (2021) Prevalence and risk factors of respiratory syncytial virus in children under 5 years of age in the WHO European Region: a systematic review and meta-analysis. J Pers Med 11:416","DOI":"10.3390\/jpm11050416"},{"key":"412_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02083-21","volume":"10","author":"YP Sun","year":"2022","unstructured":"Sun YP, Lei SY, Wang YB, Wang YZ, Qiang HS, Yin YF, Jiang ZM, Zhu M, Chen XL, Ye HM et al (2022) Molecular Evolution of Attachment Glycoprotein (G) and Fusion Protein (F) Genes of Respiratory Syncytial Virus ON1 and BA9 Strains in Xiamen, China. Microbiol Spectr 10:e0208321","journal-title":"Microbiol Spectr"},{"key":"412_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12137-1","volume":"10","author":"A Tang","year":"2019","unstructured":"Tang A, Chen Z, Cox KS, Su HP, Callahan C, Fridman A, Zhang L, Patel SB, Cejas PJ, Swoyer R et al (2019) A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun 10:4153","journal-title":"Nat Commun"},{"key":"412_CR51","doi-asserted-by":"crossref","unstructured":"Wang Q, Hong D, Li E, Cheng Z, Zhang J, Jin T, Chiu S (2025) Generation of nanobodies against the F protein of respiratory syncytial virus and establishment of an indirect immunofluorescence assay. Microbiol Spectr 13:e0278424","DOI":"10.1128\/spectrum.02784-24"},{"key":"412_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.272","volume":"2","author":"X Wen","year":"2017","unstructured":"Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE Jr, Jardetzky TS (2017) Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat Microbiol 2:16272","journal-title":"Nat Microbiol"},{"key":"412_CR53","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.chom.2023.07.002","volume":"31","author":"X Wen","year":"2023","unstructured":"Wen X, Suryadevara N, Kose N, Liu J, Zhan X, Handal LS, Williamson LE, Trivette A, Carnahan RH, Jardetzky TS et al (2023) Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode. Cell Host Microbe 31:1288\u20131300.e1286","journal-title":"Cell Host Microbe"},{"key":"412_CR54","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jviromet.2018.10.022","volume":"263","author":"Z Wen","year":"2019","unstructured":"Wen Z, Citron M, Bett AJ, Espeseth AS, Vora KA, Zhang L, DiStefano DJ (2019) Development and application of a higher throughput RSV plaque assay by immunofluorescent imaging. J Virol Methods 263:88\u201395","journal-title":"J Virol Methods"},{"key":"412_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/pro.3330","volume":"27","author":"CJ Williams","year":"2018","unstructured":"Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, Verma V, Keedy DA, Hintze BJ, Chen VB et al (2018) MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci 27:293\u2013315","journal-title":"Protein Sci"},{"key":"412_CR56","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00485-21","volume":"95","author":"G Xun","year":"2021","unstructured":"Xun G, Song X, Hu J, Zhang H, Liu L, Zhang Z, Gong R (2021) Potent human single-domain antibodies specific for a novel prefusion epitope of respiratory syncytial virus F glycoprotein. J Virol 95:e0048521","journal-title":"J Virol"},{"key":"412_CR57","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","volume":"9","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM et al (2017) A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 9:eaaj1928","journal-title":"Sci Transl Med"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00412-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00412-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00412-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:44:35Z","timestamp":1779065075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00412-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":57,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,15]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00412-w","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"QQW, ETL, DXH, TCJ, and SC are co-inventors on pending patent applications related to the 1G9. The other authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}